212 patents
Page 3 of 11
Utility
Process of Preparing Mrna-loaded Lipid Nanoparticles
15 Dec 22
The present invention provides an improved process for lipid nanoparticle formulation and mRNA encapsulation.
Shrirang Karve, Zarna Patel, Yi Zhang, Ashish Sarode, Rebecca L. Goldman, Frank DeRosa, Michael Heartlein
Filed: 5 May 22
Utility
Methods for Purification of Messenger RNA
8 Dec 22
The present invention provides, among other things, methods of purifying messenger RNA (mRNA) including the steps of subjecting an impure preparation comprising in vitro synthesized mRNA to a denaturing condition, and purifying the mRNA from the impure preparation from step (a) by tangential flow filtration, wherein the mRNA purified from step (b) is substantially free of prematurely aborted RNA sequences and/or enzyme reagents used in in vitro synthesis.
Frank DeRosa, Anusha Dias, Michael Heartlein, Shrirang Karve
Filed: 8 Jun 22
Utility
Lipid Nanoparticle Compositions and Methods for Mrna Delivery
1 Dec 22
Disclosed herein are compositions and methods for modulating the production of a protein in a target cell.
Frank DeRosa, Braydon Charles Guild, Michael Heartlein
Filed: 3 Jun 22
Utility
CFTR MRNA compositions and related methods and uses
29 Nov 22
The present disclosure relates to materials, formulations, production methods, and methods for delivery of CFTR mRNA, including but not limited to chemically modified mRNA for induction of CFTR expression, including in the mammalian lung.
Michael Heartlein, Braydon Charles Guild, Frank DeRosa, Carsten Rudolph, Christian Plank, Lianne Smith
Filed: 14 Aug 19
Utility
Lipid Nanoparticle Compositions and Methods for Mrna Delivery
17 Nov 22
Disclosed herein are compositions and methods for modulatimi the production of a protein in a target cell, The compositions and methods disclosed herein are capable of ameliorating diseases associated with protein or enzyme deficiencies.
Frank DeRosa, Braydon Charles Guild, Michael Heartlein
Filed: 3 Jun 22
Utility
Quantitative Assessment for Cap Efficiency of Messenger Rna
17 Nov 22
The present invention provides, among other things, methods of quantitating mRNA capping efficiency, particularly for mRNA synthesized in vitro.
Frank DeRosa, Anusha Dias, Michael Heartlein
Filed: 17 May 22
Utility
Lipid-derived neutral nanoparticles
15 Nov 22
Disclosed herein are novel lipids and liposomal compositions prepared using such compounds and related methods of neutralizing or otherwise modifying such liposomal compositions.
Frank DeRosa, Braydon Charles Guild, Michael Heartlein
Filed: 26 Aug 20
Utility
Mrna Therapy for the Treatment of Ocular Diseases
10 Nov 22
The present invention provides, among other things, a method of ocular delivery of messenger RNA (mRNA), comprising administering into an eye of a subject in need of delivery a composition comprising an mRNA encoding a protein, such that the administration of the composition results in expression of the protein encoded by the mRNA in the eye.
Pericles Calias, Frank DeRosa, Michael Heartlein
Filed: 3 Feb 22
Utility
Messenger Rna Vaccines and Uses Thereof
3 Nov 22
The present invention provides, among other things, methods and compositions of formulating nucleic acid-containing nanoparticles for efficient delivery of payload in vivo such that the method and compositions can be used to generate mRNA vaccines.
Shrirang Karve, Zarna Patel, Ashish Sarode, Yi Zhang, Frank DeRosa, Michael Heartlein
Filed: 28 Mar 22
Utility
Methods for Purification of Messenger RNA
3 Nov 22
The present invention provides, among other things, methods of purifying messenger RNA (mRNA) including the steps of subjecting an impure preparation comprising in vitro synthesized rnRNA to a denaturing condition, and purifying the rnRNA from the impure preparation from step (a) by tangential flow filtration, wherein the mRNA purified from step (b) is substantially free of prematurely aborted RNA sequences and/or enzyme reagents used in in vitro synthesis.
Frank DeRosa, Anusha Dias, Michael Heartlein, Shrirang Karve
Filed: 8 Jun 22
Utility
Methods for Purification of Messenger RNA
3 Nov 22
The present invention provides, among other things, methods of purifying messenger RNA (mRNA) including the steps of subjecting an impure preparation comprising in vitro synthesized rnRNA to a denaturing condition, and purifying the rnRNA from the impure preparation from step (a) by tangential flow filtration, wherein the mRNA purified from step (b) is substantially free of prematurely aborted RNA sequences and/or enzyme reagents used in in vitro synthesis.
Frank DeRosa, Anusha Dias, Michael Heartlein, Shrirang Karve
Filed: 8 Jun 22
Utility
Lipid Formulations for Delivery of Messenger Rna
3 Nov 22
Michael Heartlein, Daniel Anderson, Yizhou Dong, Frank DeRosa
Filed: 29 Jan 21
Utility
Ribose Cationic Lipids
13 Oct 22
Frank DeRosa, Shrirang Karve, Yi Zhang, Michael Heartlein
Filed: 15 May 19
Utility
TREATMENT OF CYSTIC FIBROSIS BY DELIVERY OF NEBULIZED mRNA ENCODING CFTR
13 Oct 22
The present invention provides, among other things, an improved method of treating cystic fibrosis (CF) in a human subject.
Ann Barbier, Michael Heartlein, Frank DeRoss, Jonathan Abysalh, Anusha Dias, Shrirang Karve, Zama Patel
Filed: 30 Jul 20
Utility
TREATMENT OF CYSTIC FIBROSIS BY DELIVERY OF NEBULIZED mRNA ENCODING CFTR
13 Oct 22
The present invention provides, among other things, an improved method of treating cystic fibrosis (CF) in a human subject.
Shrirang Karve, Frank DeRosa, Michael Heartlein, Zarna Patel
Filed: 11 Mar 22
Utility
Methods for purification of messenger RNA
27 Sep 22
The present invention provides, among other things, methods for purifying high quality messenger RNA (mRNA) suitable for clinical use, without using any caustic or flammable solvents.
Jonathan Abysalh, Frank DeRosa, Jorel E. Vargas, Cameron M. Smith
Filed: 15 May 20
Utility
Ribonucleic acids with 4′-thio-modified nucleotides and related methods
20 Sep 22
Disclosed are messenger RNA molecules and related compositions incorporating a 4′-thio modification in the furanose ring of at least one nucleotide residue, and methods of using these mRNAs to produce an encoded therapeutic protein in vivo and to treat or prevent diseases or disorders.
Frank DeRosa, Michael Heartlein
Filed: 25 Sep 20
Utility
Stable Liquid Lipid Nanoparticle Formulations
15 Sep 22
The present invention provides, among other things, a liquid lipid nanoparticle (LNP) formulation encapsulating mRNA encoding a peptide or polypeptide, that is resistant to aggregation and to mRNA degradation following multiple rounds of freezing at −20° C. and rethawing.
Shrirang Karve, Ashish Sarode, Natalia Vargas Montoya, Priyal Patel, Frank DeRosa
Filed: 24 Nov 21
Utility
Biodegradable lipids for delivery of nucleic acids
6 Sep 22
Frank DeRosa, Michael Heartlein
Filed: 5 Jan 21
Utility
Polyanionic delivery of nucleic acids
30 Aug 22
Michael Heartlein, Frank DeRosa, Shrirang Karve
Filed: 10 Feb 21